Safety and Efficacy of RO4929097 in Combination With Temsirolimus: A Pharmacokinetic and Pharmacodynamic Phase I Study in Patients With Advanced Solid Tumours With an Expansion of Cohort With Patients With Recurrent/Metastatic Endometrial and Renal Cell Cancers.

Trial Profile

Safety and Efficacy of RO4929097 in Combination With Temsirolimus: A Pharmacokinetic and Pharmacodynamic Phase I Study in Patients With Advanced Solid Tumours With an Expansion of Cohort With Patients With Recurrent/Metastatic Endometrial and Renal Cell Cancers.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 May 2014

At a glance

  • Drugs RG 4733 (Primary) ; Temsirolimus (Primary)
  • Indications Endometrial cancer; Renal cell carcinoma; Solid tumours; Uterine cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Oct 2013 Planned end date changed from 1 May 2014 to 1 May 2013 as reported by ClinicalTrials.gov.
    • 23 Sep 2013 Planned end date changed from 1 May 2013 to 1 May 2014 as reported by ClinicalTrials.gov.
    • 26 Mar 2013 Planned end date changed from 1 Jul 2011 to 1 May 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top